Pasithea Therapeutics Corp (KTTA) - Total Liabilities
Based on the latest financial reports, Pasithea Therapeutics Corp (KTTA) has total liabilities worth $1.42 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pasithea Therapeutics Corp - Total Liabilities Trend (2020–2024)
This chart illustrates how Pasithea Therapeutics Corp's total liabilities have evolved over time, based on quarterly financial data. See Pasithea Therapeutics Corp working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Pasithea Therapeutics Corp Competitors by Total Liabilities
The table below lists competitors of Pasithea Therapeutics Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IRLAB Therapeutics AB (publ)
ST:IRLAB-A
|
Sweden | Skr107.49 Million |
|
reAlpha Tech Corp. Common Stock
NASDAQ:AIRE
|
USA | $8.33 Million |
|
CBL International Limited Ordinary Shares
NASDAQ:BANL
|
USA | $39.56 Million |
|
SEKUR PRIVATE DATA LTD.
F:GDT0
|
Germany | €465.42K |
|
Lancartama Sejati Tbk
JK:TAMA
|
Indonesia | Rp144.72 Billion |
|
Dycasa SA
BA:DYCA
|
Argentina | AR$23.74 Billion |
|
Indonesian Tobacco Tbk PT
JK:ITIC
|
Indonesia | Rp184.04 Billion |
|
Huize Holding Ltd
NASDAQ:HUIZ
|
USA | $472.74 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Pasithea Therapeutics Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Pasithea Therapeutics Corp.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pasithea Therapeutics Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pasithea Therapeutics Corp (2020–2024)
The table below shows the annual total liabilities of Pasithea Therapeutics Corp from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.28 Million | -52.84% |
| 2023-12-31 | $2.72 Million | +1.36% |
| 2022-12-31 | $2.68 Million | +41.14% |
| 2021-12-31 | $1.90 Million | +28676.01% |
| 2020-12-31 | $6.60K | -- |
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1);… Read more